NASDAQ:JANX - Janux Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.00
  • Forecasted Upside: 186.65 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$12.21
▲ +0.77 (6.73%)

This chart shows the closing price for JANX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Janux Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JANX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JANX

Analyst Price Target is $35.00
▲ +186.65% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Janux Therapeutics in the last 3 months. The average price target is $35.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 186.65% upside from the last price of $12.21.

This chart shows the closing price for JANX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Janux Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/6/2021Bank of AmericaInitiated CoverageBuy$35.00Low
7/6/2021CowenInitiated CoverageOutperformHigh
7/6/2021Evercore ISIInitiated CoverageOutperform$35.00High
7/6/2021HC WainwrightInitiated CoverageBuy$35.00High
(Data available from 6/30/2017 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/2/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/31/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/30/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Janux Therapeutics logo
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $12.21
Low: $10.98
High: $12.67

50 Day Range

MA: $11.13
Low: $9.52
High: $13.50

52 Week Range

Now: $12.21
Low: $9.39
High: $35.93

Volume

128,724 shs

Average Volume

82,840 shs

Market Capitalization

$508.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Janux Therapeutics?

The following equities research analysts have issued research reports on Janux Therapeutics in the last year: Bank of America Co., Cowen Inc, Evercore ISI, and HC Wainwright.
View the latest analyst ratings for JANX.

What is the current price target for Janux Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Janux Therapeutics in the last year. Their average twelve-month price target is $35.00, suggesting a possible upside of 186.7%.
View the latest price targets for JANX.

What is the current consensus analyst rating for Janux Therapeutics?

Janux Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe JANX will outperform the market and that investors should add to their positions of Janux Therapeutics.
View the latest ratings for JANX.

How do I contact Janux Therapeutics' investor relations team?

The company's listed phone number is 858-750-4700 and its investor relations email address is [email protected] The official website for Janux Therapeutics is www.januxrx.com. Learn More about contacing Janux Therapeutics investor relations.